Tesamorelin: The Clinical-Grade GHRH Peptide

Tesamorelin occupies an unusual position in the GH peptide space: it's the only GHRH analogue with actual FDA approval. It's been used clinically since 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy — a medical condition, not a performance goal — but the mechanism that makes it effective in that context has made it of considerable interest to people using it for body composition and GH optimization more broadly.

What Tesamorelin Is

Tesamorelin is a synthetic analogue of GHRH (growth hormone-releasing hormone) — the same class as CJC-1295. It binds to GHRH receptors on the pituitary and stimulates the release of endogenous growth hormone.

What distinguishes tesamorelin from CJC-1295 (without DAC) is its half-life and the clinical data backing it. Tesamorelin has a half-life of roughly 26–38 minutes — similar to CJC-1295 without DAC — but the compound has been through extensive human clinical trials, meaning there's actual human pharmacokinetic and safety data rather than just animal models.

The FDA-approved product (Egrifta) is prescribed at 2 mg daily. Research peptide versions are available but carry the standard sourcing and quality caveats.

The Clinical Evidence

The clinical data on tesamorelin is substantially stronger than anything else in the GHRH peptide category.

In the pivotal trials for HIV-associated lipodystrophy, tesamorelin at 2 mg daily produced:

• Significant reductions in visceral adipose tissue (VAT) — the dangerous fat surrounding internal organs
• Increased IGF-1 levels (a downstream marker of GH activity)
• Improved lipid profiles in some patients
• Improvements in body image and quality of life measures

Crucially, these effects were observed in an adult human population with a specific metabolic condition, not in rodent models. The body composition effects of GH stimulation — particularly visceral fat reduction — are well-documented from this data.

When discontinued, visceral fat tends to return over time. This is an important practical consideration for anyone thinking about long-term tesamorelin use: it's a maintenance protocol, not a one-time course.

Tesamorelin vs. CJC-1295 / Ipamorelin

Both approaches stimulate pituitary GH release. The comparison is relevant for anyone choosing between a solo GHRH approach (tesamorelin) and the combination stack.

Tesamorelin alone: GHRH agonism only. You're amplifying GH pulse amplitude through one receptor system. The human clinical data is a meaningful advantage.

CJC-1295 + Ipamorelin: Dual mechanism — GHRH agonism plus GHRP agonism (a separate receptor, with added somatostatin blunting). Hitting both pathways generally produces a larger net GH release. More complex protocol, two compounds to manage.

The practical choice: People who want simplicity — one compound, once daily, one mechanism — often prefer tesamorelin. People who want maximum GH stimulation or who are already running a multi-peptide stack often go with the combination.

Some advanced protocols run tesamorelin as the GHRH component instead of CJC-1295, paired with ipamorelin — taking advantage of tesamorelin's clinical backing while maintaining the dual-mechanism approach.

Dosing

Standard dose: 1–2 mg subcutaneous injection daily

The FDA-approved dose for lipodystrophy is 2 mg/day. Many research protocol users run 1–2 mg daily.

Timing: Same principles as other GHRH peptides — fasted state, pre-sleep is the most common single daily injection timing to amplify the natural nocturnal GH pulse. Elevated insulin blunts the GH response, so the injection window should be at least 2 hours from a significant meal.

Cycle considerations: Unlike GHRP-containing stacks where cycling is standard practice, some people run tesamorelin on an ongoing basis (as it's used clinically for lipodystrophy), assessing periodically via IGF-1 labs. Others run 8–12 week cycles.

What to Expect

IGF-1 elevation. The most reliable and objective measure of tesamorelin's effect. Expect IGF-1 to rise meaningfully from baseline.

Visceral fat reduction. The strongest clinical evidence base for any GH peptide. Particularly relevant for people with excess abdominal fat that's resistant to diet and exercise.

Body composition changes. Lean mass and fat mass improvements, especially with adequate protein intake and training stimulus.

Sleep improvement. Common across GH-stimulating protocols; deeper sleep, improved recovery.

Water retention. Particularly early in the protocol; tends to resolve.

Carpal tunnel symptoms. Tingling or numbness in hands — a dose-dependent, GH-mediated effect. Often a signal to reduce dose rather than discontinue.

Why Daily Tracking Matters for Tesamorelin

A daily injection protocol with a physiologically active compound requires a consistent log for several reasons:

IGF-1 management. Tesamorelin produces meaningful IGF-1 elevation, and chronically elevated IGF-1 has its own risk profile. Tracking allows you to correlate dose with lab results and adjust accordingly.

Timing precision. The fasted window requirement for each injection means tracking the injection time alongside meal timing — particularly important for people whose daily schedules vary.

Side effect monitoring. Water retention, carpal tunnel symptoms, and other GH-related effects often develop gradually. A daily log makes the onset date clear, which informs whether to adjust dose or simply wait for adaptation.

Long-term protocol management. If you're running tesamorelin on a maintenance basis rather than a fixed cycle, the log becomes your only reliable record of how long you've been running, what your dose history looks like, and when you last checked labs. Milos handles daily injection logging, dose history, side effect notes, and wellness check-ins in one place.

Safety Considerations

Tesamorelin's clinical trial data is a genuine safety asset. The main concerns at therapeutic doses are:

• Fluid retention — particularly in early weeks
• Joint pain — related to increased GH and fluid shifts
• Glucose metabolism changes — GH has antagonistic effects on insulin; people with prediabetes or insulin resistance should monitor blood glucose
• IGF-1 elevation — chronically supraphysiological IGF-1 is associated with increased cancer risk in epidemiological data; this is a reason for periodic labs, not necessarily a reason to avoid the compound

Contraindications: Active malignancy, hypersensitivity to the compound, pituitary tumors.

Bottom Line

Tesamorelin is the most clinically validated GHRH peptide available and the only one with actual FDA-approved status and human trial data behind it. Its primary documented effect — visceral fat reduction through GH stimulation — is meaningful and well-supported.

The daily protocol is straightforward, but it demands consistent tracking, periodic bloodwork, and honest assessment of whether the protocol is achieving its intended effect. The clinical backing is an asset; using it without the monitoring infrastructure to take advantage of that data would be leaving the compound's best feature unused.